<DOC>
	<DOCNO>NCT00673985</DOCNO>
	<brief_summary>The main objective study assess safety effectiveness Edwards Lifesciences LifeStent nitinol self expandable stent device delivery system treatment occlusive superficial femoral artery ( SFA ) disease reduce re-intervention rate compare percutaneous transluminal angioplasty ( PTA ) alone</brief_summary>
	<brief_title>Edwards Lifesciences Self-Expanding Stent Peripheral Vascular Disease Study</brief_title>
	<detailed_description>The RESILIENT Trial dual stage clinical investigation design evaluate safety effectiveness Edwards Lifesciences self-expanding stent system . Phase 1 consists prospective , multi-center , non-randomized study peri-procedure endpoint . Phase 2 consists prospective , multi-center , randomized study 30-day primary safety endpoint 6-month primary effectiveness endpoint .</detailed_description>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Intermittent Claudication</mesh_term>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<criteria>Written informed consent approve IRB . ≥ 18 year old . Lifestylelimiting claudication define : Rutherford Cat . 13 . Target lesion ( ) denovo restenotic locate within native SFA and/or proximal popliteal artery Angiographic evidence ≥ 50 % stenosis occlusion Target RVD ≥ 4.0 mm ≤ 7.0 mm Target total length lesion series lesion ≤ 150 mm . Angiographic evidence least one vessel runoff foot . Unable conform study protocol procedures visit . Lifestylelimiting claudication/CLI ( Rutherford Cat . 46 ) Patients pregnant plan become pregnant clinical investigation Contraindication study relate medication , Ni , Ti , Ta , medium amenable pretreatment . History bleed diatheses coagulopathy . Concomitant renal failure creatinine &gt; 2.0 mg/dL . Concomitant hepatic insufficiency , thrombophlebitis , uremia , SLE , DVT time study procedure . Receiving dialysis immunosuppressive therapy . Suffered hemorrhagic stroke ≤ 6 mo prior study procedure . Prior peripheral vascular bypass surgery involve target limb . Target vessel previously stented . Target lesion ( ) receive angioplasty intervention ≤ 6 mo . prior Any noniliac percutaneous intervention ( ) &lt; 7 day prior . Currently participate investigational drug/device study . Limited life expectancy less two year . Extensive PVD precludes safe insertion sheath . Target lesion ( ) locate within aneurysm associate aneurysm vessel segment either proximal distal target lesion ( ) . Unresolved thrombus within target vessel . Poor inflow would support vascular bypass graft . Diagnosed septicemia time study procedure . Additional percutaneous interventional procedure ( cardiac/peripheral ) plan ≤ 30 day follow procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>SFA , Edwards , Popliteal , LifeStent , PTA , Nitinol</keyword>
</DOC>